Resources Repository
-
Resource PackPublication, Teaching Resource 2017Resource Pack: CEA Herpes Zoster Vaccine
This resource pack on the cost-effectiveness of herpes zoster vaccination was curated to support Dr. …
This resource pack on the cost-effectiveness of herpes zoster vaccination was curated to support Dr. Lisa Prosser's seminar on November 9, 2017 at the Center for Health Decision Science. Dr. Prosser discussed an economic evaluation of vaccination against herpes zoster. Herpes zoster—more commonly known as shingles—presents a major burden for older Americans but, until recently, the only available vaccine (Zoster Vaccine Live, ZVL) was relatively ineffective past 10 years. A recently approved vaccine–herpes zoster subunit…
Preferences/Values | Science/Technology | Europe | Costing Methods | Health Outcomes | Mathematical Models | Cost-Effectiveness Analysis | Infectious Diseases | Clinical Care | Culture/Society | Health/Medicine | North America -
Resource PortalPublication, Teaching Resource 2017Immunization Financing: A Resource Guide
This resource guide compiles 26 briefs on topics related to the cost and financing of …
This resource guide compiles 26 briefs on topics related to the cost and financing of national immunization programs in low- and middle-income countries. The guide provides information and analysis to help advocates, policymakers, and program managers assess different financing options, approaches to strategic purchasing, and strategies for policy change, incorporating recent country experience in these areas. The guide is an update to the Immunization Financing Toolkit: A Resource for Policy-Makers and Program Managers, published by…
Priority Setting/Ethics | Science/Technology | Sub-Saharan Africa | Costing Methods | Infectious Diseases | Health Systems | Global Governance | Economics/Finance | Health/Medicine | Middle East & North Africa | Latin America & Caribbean | Asia & Pacific | College | Graduate | Doctoral | Professional | Decision Making/Leadership | Policy Translation | Quantitative Literacy -
GuidelinesPublication 2016Estimating Health-State Utility for Economic Models: ISPOR Task Force Report
Cost-utility models are increasingly used in many countries to establish whether the cost of a …
Cost-utility models are increasingly used in many countries to establish whether the cost of a new intervention can be justified in terms of health benefits. Health-state utility (HSU) estimates (the preference for a given state of health on a cardinal scale where 0 represents dead and 1 represents full health) are typically among the most important and uncertain data inputs in cost-utility models. Clinical trials represent an important opportunity for the collection of health-utility data.…
Preferences/Values | Science/Technology | Europe | Health Outcomes | Mathematical Models | Cost-Effectiveness Analysis | Technology Assessment | Health Systems | Health/Medicine | North America -
ArticlePublication 2016Accounting for Technical, Ethical, and Political Factors in Priority Setting
This article investigates two cases of priority setting to explore how, in addition to technical …
This article investigates two cases of priority setting to explore how, in addition to technical considerations, ethical and political factors shape the allocation of health resources. First, they discuss how Thai authorities adjudicated a coverage decision for HLA-B*1502 screening, which meets the national cost-effectiveness threshold for only some of the conditions it can detect. Second, they consider England’s Cancer Drugs Fund to investigate the interplay of technical decision making and political reality. The findings suggest four concluding…
Priority Setting/Ethics | Science/Technology | Europe | Cost-Effectiveness Analysis | Chronic Disease/Risk | Health Systems | Policy/Regulation | Climate/Environment | Government/Law | Health/Medicine | Global -
ReviewPublication 2013Valuing the Economic Benefits of Complex Interventions
This is a review of economic evaluations of complex health interventions. Complex interventions, involving interlinked …
This is a review of economic evaluations of complex health interventions. Complex interventions, involving interlinked packages of care, challenge the application of current methods of economic evaluation that focus on measuring only health gain. The authors find that complex interventions may be problematic on two levels. First, the complexity means the intervention may not fit into one of the current appraisal systems, and/or second, maximizing health is not the only objective. This paper discusses the…
Preferences/Values | Science/Technology | Europe | Decision Analysis | Health Systems | Policy/Regulation | Economics/Finance | Government/Law | Health/Medicine -
ReviewPublication 2013Public Health Economics: Review of Guidance for Economic Evaluation
This is a systematic review of published guidance for the economic evaluation of public health …
This is a systematic review of published guidance for the economic evaluation of public health interventions. Public Health Economics is the science and art of supporting decision making as to how society can use its available resources to advance health, and minimize opportunity cost. In this review, the authors identified 5 international guidance documents, 7 UK guidance documents and 4 documents by individual commentators. The papers reviewed identify the main methodological challenges that face analysts…
Priority Setting/Ethics | Science/Technology | Europe | Costing Methods | Cost-Effectiveness Analysis | Health Systems | Policy/Regulation | Economics/Finance | Health/Medicine -
ArticlePublication 2011Health and Economic Impact of HPV 16/18 Vaccination and Cervical Cancer Screening in Eastern Africa
In this article the authors use epidemiologic data from Kenya, Mozambique, Tanzania, Uganda, and Zimbabwe …
In this article the authors use epidemiologic data from Kenya, Mozambique, Tanzania, Uganda, and Zimbabwe to develop models of HPV-related infection and disease. For each country, they assessed HPV vaccination of girls before age 12 followed by screening with HPV DNA testing once, twice, or three times per lifetime (at ages 35, 40, 45). For women over age 30, they assessed only screening (with HPV DNA testing up to three times per lifetime or VIA…
Calibration/Validation | Science/Technology | Sub-Saharan Africa | Microsimulation | Cost-Effectiveness Analysis | Infectious Diseases | Chronic Disease/Risk | Clinical Care | Economics/Finance | Health/Medicine